Obesity Drugs Cut Addiction Deaths by 50% in VA Study

Medications that millions take for weight loss might also be saving lives from addiction in ways doctors never expected.

A groundbreaking study published in The BMJ analyzed health records from over 600,000 US military veterans and found stunning results. People taking GLP-1 drugs like Ozempic and Wegovy had a 50% lower risk of dying from substance abuse compared to those taking different diabetes medications.

The news gets even better. Among people with no history of addiction, those taking GLP-1 drugs were significantly less likely to develop substance use problems over three years. The risk dropped 18% for alcohol, 20% for cocaine and nicotine, and 25% for opioids.

Researchers at the VA St Louis Health Care System compared two groups of people with type 2 diabetes. One group took GLP-1 medications while the other took a different class of diabetes drugs. They tracked both groups for up to three years.

"The consistency of effect across multiple substances, which have different mechanisms of action, was quite a revelation," says study co-author Ziyad Al-Aly, a clinical epidemiologist at the VA.

The findings match what doctors are hearing directly from patients. "We have our patients telling us, 'I don't feel like I want to smoke anymore. I don't really have the interest in drinking anymore,'" says Daniel Drucker, an endocrinologist at the University of Toronto.

The Ripple Effect

This discovery could transform how we treat the addiction crisis that affects millions worldwide. The VA's massive database made it possible to spot patterns across different types of substances, from alcohol to opioids, all showing similar protective effects.

The study adds to growing evidence that GLP-1 drugs do far more than control blood sugar and weight. Small clinical trials and countless patient reports have hinted at these benefits for months.

Specialists say larger randomized controlled trials are still needed to confirm the findings. But for people struggling with both metabolic disorders and substance use, these medications might offer a double benefit that could change lives.

The research opens a door to hope for millions facing addiction, showing that solutions sometimes come from unexpected places.